bevacizumab

(redirected from Avastin)
Also found in: Medical.

bev·a·ciz·u·mab

 (bĕv′ə-sĭz′ə-măb′)
n.
A humanized monoclonal antibody that acts as an angiogenesis inhibitor, used intravenously to treat metastatic colorectal cancer and certain other types of cancer.

[beva-, origin unknown + -ci-, cardiovascular infix + -zu-, humanized + -m(onoclonal) a(nti)b(ody).]
References in periodicals archive ?
Genentech, a member of the Roche Group announced results from the positive Phase III IMmotion151 study of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.
M2 EQUITYBITES-December 11, 2017-Roche's combination of Tecentriq and Avastin plus chemotherapy extends lung cancer patients' lives in Phase III study
M2 PHARMA-December 11, 2017-Roche's combination of Tecentriq and Avastin plus chemotherapy extends lung cancer patients' lives in Phase III study
Roche announced today that the European Commission has approved the use of Avastin (bevacizumab) in combination with Tarceva (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations.
THE PHARMACEUTICAL industry has played a significant role in blocking doctors from accessing cancer drug Avastin (bevicizumab) for UK patients with age-related macular degeneration (AMD), according to an investigative report published earlier this month in the British Medical Journal (BMJ).
Last year Annie rented a room in London after her health board refused her the cancer drug Avastin.
The pharmaceutical giants did so "to benefit a much more expensive product, Lucentis, artificially differentiating between the two products," it said, including by steering health services and doctors away from Avastin by describing it as more dangerous.
14 ( ANI ): Researchers have found that adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs resulted in a sharp decline in women suffering from "triple-negative" breast cancer.
A two-year trial found that anti-cancer drug Avastin is as good a treatment for two degenerative eye conditions as a tailor-made product that is nearly 12 times more expensive.
Despite its use in almost every country in the Western world, Avastin has been rejected by The Scottish Medical Consortium (SMC).
QUETTA -- Swiss drugmaker Roche's cancer drug Avastin failed to make a statistically significant difference to survival rates of patients with a common form of brain cancer in a late-stage study, the company said on Saturday.